MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-MP-23-0002155
Erawat Pharma Limited - healthcare in Indore, Madhya Pradesh, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹78.37 Cr
▲ 14% YoY
Net loss · FY 2025
₹2.51 Cr
Net margin -3.2%
EBITDA · FY 2025
₹3.24 Cr
EBITDA margin 4.1%
Authorised capital
₹6.95 Cr
Registered with MCA
Paid-up capital
₹6.75 Cr
Issued & subscribed
Open charges
₹50 Cr
Satisfied ₹29.78 Cr
Company age
33 yrs
Est. 1993
Employees · EPFO
175
Provident fund records
About Erawat Pharma Limited
Data last updated:
Erawat Pharma Limited is a public limited company based in Indore, Madhya Pradesh, India. It operates in the medical consumables and supplies segment of the healthcare sector. It was incorporated on 01 March 1993 and has been in existence for over 33 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN U02423MP1993PLC007538. Its GSTIN is 23AAACE3757F1ZY (Madhya Pradesh).
The company has an authorised share capital of ₹6.95 Cr and a paid-up capital of ₹6.75 Cr. It was formerly known as Erawat Pharma Private Limited. It is led by directors including Hemchandra Jain (Managing Director) and Amit Jain (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 12C F A Scheme No. 94 Ring Road, Indore, Madhya Pradesh, India – 452010.
As per the financials filed for FY 2025, the company reported a revenue of ₹78.37 Cr, a growth of 14% compared to the previous year. For the same year it recorded a net loss of ₹2.51 Cr (net margin -3.2%) and EBITDA of ₹3.24 Cr (EBITDA margin 4.1%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years and 12% over five years.
The company has about 175 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Erawat Group and Erawat. As per MCA filings, the company has open charges of ₹50 Cr and satisfied charges of ₹29.78 Cr on record. Court records list 12 cases involving the company, including 10 filed by the company and 2 filed against it; 7 cases are pending. The company has 15 deals on record (11 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹2.16 Cr; the latest was in March 2022. Its 5 peer companies in the Healthcare industry (Medical Consumables), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 1 smaller; the largest is Angstrom Biotech Private Limited with revenue of ₹86.9 Cr. The company has 4 MSME Form 1 returns on record between 2019 and 2020, listing 66 overdue payments to 45 micro and small suppliers.
Erawat Pharma Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MP-23-0002155). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website erawat.com.
Company details
CIN U02423MP1993PLC007538
Registration Number 007538
Incorporation Date 01 March 1993
ROC Gwalior
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MP-23-0002155
Key People
Hemchandra Jain Managing Director Amit Jain Whole-Time Director Abhijeet Jain Whole-Time Director Recognitions & Rankings of Erawat Pharma
Contact details
Erawat Pharma Limited's registered office is in Indore, Madhya Pradesh. Its website is erawat.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address12C F A Scheme No. 94 Ring Road, Indore, Madhya Pradesh, India – 452010
- IndustryHealthcare, Medical Consumables & Supplies
To see the full contact details of Erawat Pharma Limited, buy the company report.
Comprehensive company report
Erawat Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Erawat Pharma operates two associated brands: Erawat Group and Erawat. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures hard gelatin capsules and capsule manufacturing machines. | erawatgroup.com | |
| Manufacturing of empty hard capsules and HPMC capsules for pharmaceutical use in India. | erawat.com |
Business activity
The main business activity of Erawat Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Erawat Pharma Limited, buy the company report.
Financials of Erawat Pharma Limited
FY 2024 filings availableErawat Pharma Limited reported revenue of ₹78.37 Cr (up 14% YoY) for FY 2025.
Revenue · FY 2025
₹78.37 Cr ▲ 14%
Net loss · FY 2025
₹2.51 Cr margin -3.2%
EBITDA · FY 2025
₹3.24 Cr margin 4.1%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 14%
3 years · compounded
▲ 2%
5 years · compounded
▲ 12%
EBITDA CAGR growth
1 year
▲ 30%
3 years · compounded
▼ 41%
5 years · compounded
▼ 2%
Revenue has grown at a compounded annual rate (CAGR) of 12% over five years, including 14% growth in the latest year. EBITDA rose 30% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹3.24 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹2.51 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 4.1% | ||||
| Net Profit Margin | -3.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Erawat Pharma Limited, buy the company report.
Board of directors of Erawat Pharma Limited
Erawat Pharma has 7 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Amit Jain Also directs: Swasti Kalyan Foundation, Anant Pharmacs Private Limited | Whole-Time Director | 01 Oct 2018 | 8 Years 0 Months | Current |
| Vasant Raj Solanki | Director | 16 Aug 1994 | 32 Years 2 Months | Current |
| Devindar Singh Sodhi Also directs: Dashmesh Sonail Healthcare Private Limited | Director | 30 Apr 1997 | 29 Years 5 Months | Current |
| Hemchandra Jain | Managing Director | 01 Mar 1993 | 33 Years 7 Months | Current |
| Abhijeet Jain Also directs: Swasti Kalyan Foundation, Anant Pharmacs Private Limited | Whole-Time Director | 01 Oct 2018 | 8 Years 0 Months | Current |
| Abhishek Jain Also directs: Swasti Kalyan Foundation, Jhanjhari Sons Leasing and Investment Pvt Ltd, Anant Formulations Private Limited and 1 more | Whole-Time Director | 11 Jul 2003 | 23 Years 3 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Erawat Pharma Limited is compared with the 5 companies closest to it by revenue in the Healthcare industry (Medical Consumables), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Angstrom Biotech Private Limited | ₹86.9 Cr (FY 2022) | -2.0% | Vadodara, Gujarat, India | |||
| Sunil Healthcare Limited | ₹84.76 Cr (FY 2025) | -11.0% | New Delhi, Delhi, India | |||
| Adeshwar Meditex Limited | ₹83.97 Cr (FY 2025) | 5.0% | Mumbai, Maharashtra, India | |||
| Beacon Diagnostics Pvt Ltd | ₹82.21 Cr (FY 2025) | -1.0% | Navsari, Gujarat, India | |||
| Erawat Pharma Limitedthis company | ₹78.37 Cr (FY 2025) | -₹2.51 Cr | -3.2% | 14.0% | 175 | Indore, Madhya Pradesh, India |
| Aegis Lifesciences Private Limited | ₹73.4 Cr (FY 2025) | 28.0% | Ahmedabad, Gujarat, India |
To see the full peer comparison of Erawat Pharma Limited, buy the company report.
Auditor
Erawat Pharma Limited is audited by Mahesh Virendra & Co. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Mahesh Virendra & Co. | FY 2023 | 009130C |
Shareholding
The shareholding of Erawat Pharma Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Erawat Pharma Limited, buy the company report.
Charges & borrowings
Open charges
₹50 Cr
Satisfied charges
₹29.78 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Nov 2024 | 101006106 | Sidbi | ₹81.76 Lakh | Open | |
| 26 Feb 2024 | 100886118 | Others | ₹89.08 Lakh | Open | |
| 22 Nov 2023 | 100854597 | Sidbi | ₹1.28 Cr | Open | |
| 13 Apr 2023 | 100713988 | Others | ₹8.24 Cr | Open | |
| 21 Oct 2022 | 100628027 | Others | ₹6 Cr | Open |
To see the full charge records of Erawat Pharma Limited, buy the company report.
Total charge records: 25 View all charges
Deals & funding
Erawat Pharma Limited has 15 deals on record (11 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹2.16 Cr; the latest was in March 2022.
Total deals
15
Secondary share transfers
11
Funding rounds
3
Rights issue
1
Disclosed funding
₹2.16 Cr
Deals on record (5 of 15)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2018 | Secondary share transfer | Undisclosed | Buyer: Hem Chandra Jain Huf, an individual Seller: Balaji Resources and Trading Limited , 3 individuals |
| Mar 2012 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Hem Chandra Jain Huf, Zankar Leasing and Financing Pvt Ltd , 2 individuals |
| May 2008 | Secondary share transfer | Undisclosed | Buyer: Zankar Leasing and Financing Pvt Ltd , 3 individuals Seller: Erawat Engineering Pvt Ltd |
| Apr 2008 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: Erawat Engineering Pvt Ltd |
| Feb 2008 | Secondary share transfer | Undisclosed | Buyer: Balaji Resources and Trading Limited , 3 individuals Seller: 4 individuals |
To see the full deal history of Erawat Pharma Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Erawat Pharma Limited has 12 court cases on record: 10 filed by Erawat Pharma, 2 filed against it. 7 cases are pending and 5 are disposed.
Total cases
12
Filed by the company
10
Filed against the company
2
Pending
7
Disposed
5
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 12 | 2 | 7 |
Cases on record (5 of 12)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai City Civil Court, Maharashtra | Interim or miscellaneous application | Filed against the company by Royal Palms India Pvt. Ltd. Through Mr. Stephen David Nadar | Pending |
| District court, Mumbai City Civil Court, Maharashtra | Court case (Sum.Civ.Suit) | Filed against the company by Royal Palms India Pvt. Ltd. Through Mr. Stephen David Nadar | Pending |
| District court, Bhopal, Madhya Pradesh | Court case (MJC AV) | Filed by the company against Eurolife Healthcare Pvt Ltd | Pending |
| District court, Indore, Madhya Pradesh | Court case (UN CR) | Filed by the company against Pureca Laboratories Pvt.Ltd and 4 others | Pending |
| District court, Indore, Madhya Pradesh | Court case (UN CR) | Filed by the company against individuals | Pending |
To see the full case history of Erawat Pharma Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Erawat Pharma Limited was last rated by Crisil on 09 Mar 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 09 Mar 2020 |
To see the full credit ratings and regulatory alerts of Erawat Pharma Limited, buy the company report.
MSME payment delays
Erawat Pharma Limited has 4 MSME Form 1 returns on record between 2019 and 2020, listing 66 overdue payments to 45 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 45)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| an individual supplier | |||
| an individual supplier | |||
| Anant Pharmac and Packaging System | |||
| an individual supplier |
To see the full MSME payment records of Erawat Pharma Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Erawat Pharma Limited has a workforce of 175 employees on its EPFO records as of Apr 05, 2024, across 1 active EPFO establishment.
Employee count
175
Active EPFO establishments
1
Employee growth
4.17%
GST
Erawat Pharma has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AAACE3757F1ZY | Madhya Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Erawat Pharma Limited, buy the company report.
Recent activity
Erawat Pharma Limited has 14 board changes on record since 1993: 7 appointments and 7 cessations. The latest: Meena Jain ceased to be Additional Director on 26 Nov 2021.
Charges
A charge with Sidbi amounted to Rs. 0.82 Cr with Charge ID 101006106 was registered on 20 Nov 2024.
AGM
Erawat Pharma Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Charges
A charge with Others of Rs. 0.89 Cr registered on 26 Feb 2024 with Charge ID 100886118 was modified on 09 Aug 2024.
Charges
A charge with Others of Rs. 6.00 Cr registered on 21 Oct 2022 with Charge ID 100628027 was modified on 09 Aug 2024.
Charges
A charge with Others of Rs. 0.69 Cr registered on 21 Oct 2022 with Charge ID 100627269 was modified on 09 Aug 2024.
Charges
A charge with Others of Rs. 0.43 Cr registered on 21 Oct 2022 with Charge ID 100627262 was modified on 09 Aug 2024.
Charges
A charge with Others of Rs. 11.92 Cr registered on 14 Aug 2021 with Charge ID 100474373 was modified on 09 Aug 2024.
Charges
A charge with Others of Rs. 9.96 Cr registered on 14 Aug 2021 with Charge ID 100474356 was modified on 09 Aug 2024.
Filing
Erawat Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Gwalior.
Charges
A charge with Others amounted to Rs. 0.89 Cr with Charge ID 100886118 was registered on 26 Feb 2024.
Charges
A charge with Others of Rs. 6.00 Cr registered on 02 Aug 2022 with Charge ID 100602994 was modified on 26 Feb 2024.
Charges
A charge with Others of Rs. 8.24 Cr registered on 13 Apr 2023 with Charge ID 100713988 was modified on 01 Feb 2024.
52 earlier events are in the company report.
Frequently asked questions
Erawat Pharma is an active public limited company based in Indore, Madhya Pradesh, India. The company works in medical consumables and supplies, within the healthcare industry. It was incorporated on 01 March 1993 (33+ years old) and is registered under CIN U02423MP1993PLC007538.
Erawat Pharma has 7 current directors:
- Hemchandra Jain - Managing Director
- Amit Jain - Whole-Time Director
- Abhijeet Jain - Whole-Time Director
- Abhishek Jain - Whole-Time Director
- Vasant Raj Solanki - Director
- Devindar Singh Sodhi - Director
- Meena Jain - Director
The latest financial statements of Erawat Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Erawat Pharma is 23AAACE3757F1ZY, registered in Madhya Pradesh.
The CIN (Corporate Identification Number) of Erawat Pharma is U02423MP1993PLC007538. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Erawat Pharma has 12 court cases on record: 10 filed by the company and 2 filed against it. 7 are pending.
Erawat Pharma was incorporated on 01 March 1993, making it 33+ years old. It is registered with the Registrar of Companies, Gwalior.
Erawat Pharma has 15 deals on record (11 secondary share transfers, 3 funding rounds, 1 rights issue), with disclosed funding of ₹2.16 Cr; the latest was in March 2022.
The peers of Erawat Pharma by revenue are Angstrom Biotech Private Limited, Sunil Healthcare Limited, Adeshwar Meditex Limited, Beacon Diagnostics Pvt Ltd, Aegis Lifesciences Private Limited, all in the Healthcare industry (Medical Consumables), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Meena Jain ceased to be Additional Director on 26 Nov 2021. Raj Kirtani ceased to be Director on 18 Oct 2021. Meena Jain was appointed as Director on 15 Jun 2021. Erawat Pharma has 14 board changes on record in total.
Yes, Erawat Pharma is registered as a medium enterprise under Udyam registration (number: UDYAM-MP-23-0002155).
Erawat Pharma has 4 MSME Form 1 returns on record between 2019 and 2020, listing 66 overdue payments to 45 micro and small suppliers. The latest return was filed on 01 Jan 2021.